Menlo Advisors’s AbbVie ABBV Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | $7.1M | Sell |
38,252
-500
| -1% | -$92.9K | 3.83% | 11 |
|
|
2025
Q1 | $8.12M | Sell |
38,752
-150
| -0.4% | -$29.2K | 3.86% | 11 |
|
|
2024
Q4 | $6.91M | Hold |
38,902
| – | – | 3.53% | 12 |
|
|
2024
Q3 | $7.68M | Hold |
38,902
| – | – | 3.95% | 11 |
|
|
2024
Q2 | $6.67M | Sell |
38,902
-200
| -0.5% | -$33.1K | 3.7% | 11 |
|
|
2024
Q1 | $7.12M | Buy |
39,102
+1,430
| +4% | +$246K | 4.08% | 11 |
|
|
2023
Q4 | $5.84M | Hold |
37,672
| – | – | 3.59% | 12 |
|
|
2023
Q3 | $5.62M | Hold |
37,672
| – | – | 3.69% | 11 |
|
|
2023
Q2 | $5.08M | Sell |
37,672
-330
| -0.9% | -$48.4K | 3.2% | 13 |
|
|
2023
Q1 | $6.06M | Hold |
38,002
| – | – | 4.16% | 9 |
|
|
2022
Q4 | $6.14M | Hold |
38,002
| – | – | 4.61% | 10 |
|
|
2022
Q3 | $5.1M | Sell |
38,002
-645
| -2% | -$92.6K | 3.58% | 14 |
|
|
2022
Q2 | $5.92M | Hold |
38,647
| – | – | 3.92% | 10 |
|
|
2022
Q1 | $6.26M | Hold |
38,647
| – | – | 3.31% | 11 |
|
|
2021
Q4 | $5.23M | Sell |
38,647
-940
| -2% | -$111K | 2.6% | 14 |
|
|
2021
Q3 | $4.27M | Hold |
39,587
| – | – | 2.26% | 18 |
|
|
2021
Q2 | $4.46M | Sell |
39,587
-460
| -1% | -$51.8K | 2.4% | 18 |
|
|
2021
Q1 | $4.33M | Sell |
40,047
-2,000
| -5% | -$214K | 2.58% | 17 |
|
|
2020
Q4 | $4.5M | Hold |
42,047
| – | – | 2.98% | 14 |
|
|
2020
Q3 | $3.68M | Hold |
42,047
| – | – | 2.89% | 14 |
|
|
2020
Q2 | $4.13M | Sell |
42,047
-70
| -0.2% | -$6.16K | 3.22% | 12 |
|
|
2020
Q1 | $3.21M | Sell |
42,117
-1,495
| -3% | -$127K | 3.03% | 15 |
|
|
2019
Q4 | $3.86M | Hold |
43,612
| – | – | 2.52% | 21 |
|
|
2019
Q3 | $3.3M | Sell |
43,612
-150
| -0.3% | -$10.3K | 2.31% | 23 |
|
|
2019
Q2 | $3.18M | Sell |
43,762
-91
| -0.2% | -$7.15K | 2.19% | 24 |
|
|
2019
Q1 | $3.53M | Sell |
43,853
-590
| -1% | -$48.3K | 2.52% | 21 |
|
|
2018
Q4 | $4.1M | Sell |
44,443
-4,392
| -9% | -$386K | 3.18% | 15 |
|
|
2018
Q3 | $4.62M | Hold |
48,835
| – | – | 3.12% | 17 |
|
|
2018
Q2 | $4.52M | Hold |
48,835
| – | – | 3.33% | 16 |
|
|
2018
Q1 | $4.62M | Sell |
48,835
-21,350
| -30% | -$2.35M | 3.34% | 10 |
|
|
2017
Q4 | $6.79M | Sell |
70,185
-1,548
| -2% | -$146K | 4.91% | 4 |
|
|
2017
Q3 | $6.37M | Sell |
71,733
-2,340
| -3% | -$178K | 4.85% | 3 |
|
|
2017
Q2 | $5.37M | Hold |
74,073
| – | – | 3.95% | 8 |
|
|
2017
Q1 | $4.83M | Hold |
74,073
| – | – | 3.63% | 10 |
|
|
2016
Q4 | $4.64M | Sell |
74,073
-865
| -1% | -$52.8K | 3.73% | 11 |
|
|
2016
Q3 | $4.73M | Sell |
74,938
-763
| -1% | -$49.4K | 3.79% | 12 |
|
|
2016
Q2 | $4.69M | Sell |
75,701
-110
| -0.1% | -$6.7K | 3.98% | 10 |
|
|
2016
Q1 | $4.33M | Sell |
75,811
-755
| -1% | -$42.1K | 3.97% | 10 |
|
|
2015
Q4 | $4.54M | Sell |
76,566
-5,930
| -7% | -$342K | 3.99% | 9 |
|
|
2015
Q3 | $4.49M | Sell |
82,496
-1,420
| -2% | -$92.4K | 3.53% | 11 |
|
|
2015
Q2 | $5.64M | Sell |
83,916
-100
| -0.1% | -$6.53K | 3.94% | 10 |
|
|
2015
Q1 | $4.92M | Buy |
84,016
+24,694
| +42% | +$1.49M | 3.51% | 13 |
|
|
2014
Q4 | $3.88M | Sell |
59,322
-768
| -1% | -$48.4K | 2.76% | 14 |
|
|
2014
Q3 | $3.47M | Sell |
60,090
-595
| -1% | -$33K | 2.52% | 18 |
|
|
2014
Q2 | $3.42M | Hold |
60,685
| – | – | 2.46% | 18 |
|
|
2014
Q1 | $3.12M | Sell |
60,685
-720
| -1% | -$36.4K | 2.34% | 19 |
|
|
2013
Q4 | $3.24M | Hold |
61,405
| – | – | 2.42% | 18 |
|
|
2013
Q3 | $2.75M | Hold |
61,405
| – | – | 2.14% | 22 |
|
|
2013
Q2 | $2.54M | Buy |
+61,405
| New | +$2.69M | 2.14% | 21 |
|
Other funds holding ABBV
Menlo Advisors's ABBV Position: Q2 2025 in Review
Menlo Advisors reduced its AbbVie (ABBV) stake by 1.3% in Q2 2025, selling an estimated $92.9K and leaving 38,252 shares worth $7.1M. The position accounts for 3.83% of the portfolio, ranked #11.
Menlo Advisors first reported a position in ABBV in Q2 2013 and has held it in 49 quarters since. The position peaked at $8.12M in Q1 2025. 3,781 funds tracked by Wall St. Rank hold ABBV as of Q2 2025.
- Menlo Advisors held 38,252 shares of AbbVie worth $7.1M as of Q2 2025.
- Menlo Advisors sold 500 AbbVie shares in Q2 2025, an estimated $92.9K.
- AbbVie made up 3.83% of Menlo Advisors's portfolio in Q2 2025, its #11 holding.
- Menlo Advisors first reported a position in AbbVie in Q2 2013 and has held it in 49 quarters since.
- Menlo Advisors's AbbVie position peaked at $8.12M in Q1 2025.
- 3,781 funds tracked by Wall St. Rank held AbbVie as of Q2 2025.
Based on Menlo Advisors's 13F filing for Q2 2025, filed 6 Aug 2025.